Can-Fite BioPharma Future Growth

Future criteria checks 0/6

Can-Fite BioPharma's earnings are forecast to decline at 3.5% per annum while its annual revenue is expected to grow at 2.2% per year.

Key information

-3.5%

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	23.7%
Revenue growth rate	2.2%
Future return on equity	n/a
Analyst coverage	Low
Last updated	02 Apr 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

NYSEAM:CANF - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1	-8	N/A	N/A	1
12/31/2025	1	-7	N/A	N/A	1
12/31/2024	1	-7	N/A	N/A	1
12/31/2023	1	-8	-8	-8	N/A
9/30/2023	1	-9	N/A	N/A	N/A
6/30/2023	1	-10	-10	-10	N/A
3/31/2023	1	-10	N/A	N/A	N/A
12/31/2022	1	-10	-11	-11	N/A
9/30/2022	1	-14	N/A	N/A	N/A
6/30/2022	1	-15	-12	-12	N/A
3/31/2022	1	-16	N/A	N/A	N/A
12/31/2021	1	-15	-10	-10	N/A
9/30/2021	1	-12	N/A	N/A	N/A
6/30/2021	1	-11	-7	-7	N/A
3/31/2021	1	-12	N/A	N/A	N/A
12/31/2020	1	-15	-12	-12	N/A
9/30/2020	1	-13	N/A	N/A	N/A
6/30/2020	2	-17	-14	-14	N/A
3/31/2020	2	-13	N/A	N/A	N/A
12/31/2019	2	-13	-11	-11	N/A
9/30/2019	2	-11	N/A	N/A	N/A
6/30/2019	4	-8	-8	-8	N/A
3/31/2019	3	-7	N/A	N/A	N/A
12/31/2018	4	-7	-4	-4	N/A
9/30/2018	4	-5	N/A	N/A	N/A
6/30/2018	2	-6	-5	-5	N/A
3/31/2018	1	-5	N/A	N/A	N/A
12/31/2017	1	-6	-9	-9	N/A
9/30/2017	1	-6	N/A	N/A	N/A
6/30/2017	0	-9	N/A	-9	N/A
3/31/2017	0	-7	N/A	N/A	N/A
12/31/2016	0	-8	N/A	-9	N/A
9/30/2016	0	-5	N/A	N/A	N/A
6/30/2016	0	-6	N/A	-8	N/A
3/31/2016	0	-6	N/A	N/A	N/A
12/31/2015	0	-6	N/A	-5	N/A
9/30/2015	0	-7	N/A	N/A	N/A
6/30/2015	0	-5	N/A	-5	N/A
3/31/2015	N/A	-5	N/A	N/A	N/A
12/31/2014	N/A	-6	N/A	-7	N/A
9/30/2014	N/A	-7	N/A	N/A	N/A
6/30/2014	N/A	-8	N/A	-9	N/A
3/31/2014	N/A	-8	N/A	N/A	N/A
12/31/2013	N/A	-8	N/A	-9	N/A
9/30/2013	N/A	-7	N/A	-7	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CANF is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CANF is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CANF is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CANF's revenue (2.2% per year) is forecast to grow slower than the US market (8.2% per year).

High Growth Revenue: CANF's revenue (2.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CANF's Return on Equity is forecast to be high in 3 years time

Can-Fite BioPharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Can-Fite BioPharma Ltd. Reports New Data on Namodenoson’s Anti-Obesity Mechanism of Action

Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson

Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients

Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Biopharma Ltd. Provides Business Update

Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal

Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of A Fondazione Telethon and Naples University Researcher Showing Piclidenoson Is Efficacious in Treating Lowe Syndrome

Can-Fite Biopharma Ltd. Submits Pediatric Plan to U.S. Food and Drug Administration to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

Can-Fite Biopharma Ltd. Receives U.S. FDA's Go Ahead for Piclidenoson Psoriasis Registration Plan

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Can-Fite BioPharma Ltd. to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

Can-Fite BioPharma Ltd. to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

Can-Fite Biopharma Ltd. Announces Namodenoson Is Approved for Compassionate Use in the Treatment of Liver Cancer in Israel and Romania

Can-Fite BioPharma Ltd. Announces Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies

Can-Fite BioPharma Ltd. Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; U.S. Food and Drug Administration Submission to Follow

Can-Fite Biopharma Ltd Provides Update on Its Clinical Program for Namodenoson in the Treatment of Hepatocellular Carcinoma

Can-Fite BioPharma Ltd.: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

Can-Fite BioPharma Ltd’s Drug Namodenoson Approves for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

Can-Fite BioPharma Ltd. Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through Its Partner Vetbiolix

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Can-Fite BioPharma Ltd. to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Can-Fite BioPharma Ltd. Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT Study in Moderate to Severe Psoriasis

Can-Fite BioPharma Ltd. Receives Key NASH Patent in Israel

Can-Fite Biopharma Ltd. Announces It Is Developing A Topical Psoriasis Treatment with Piclidenoson, Its Phase III Psoriasis Oral Drug Candidate

Can-Fite BioPharma Ltd. Announces Top Line Data from its Phase III Comfort™ Study of Piclidenoson in Treatment of Moderate-To-Severe Plaque Psoriasis to Be Release in the Second Quarter of 2022

Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

Can-Fite BioPharma Ltd. Announces Pre-Clinical Studies with Skin Cells, Modeling Psoriasis in Humans

Can-Fite Biopharma Ltd Files Patent Applications for the Treatment of Various Advanced Solid Tumors

Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

Can-Fite Biopharma Ltd. Announces Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January

Can-Fite Biopharma Ltd. Commences Clinical Study for the Treatment of Canine Osteoarthritis

Can-Fite BioPharma Ltd. Completes Patient Enrollment in Phase III Psoriasis Study

Can-Fite BioPharma Ltd Receives Notice of Patent Allowance in China for NASH Treatment

Can-Fite Biopharma Ltd. to Initiate Phase IIb Nash Study with its Drug Candidate Namodenoson

Can-Fite BioPharma Ltd. Provides Clinical Update

Can-Fite Biopharma Ltd. Announces That 75% of Patients Enrolled in Its Phase III Comfort Study

Can-Fite BioPharma Ltd. Announces New Data from Preclinical Study of Its Drug Candidate CF602 in the Treatment of Erectile Dysfunction in Diabetes Experimental Model

Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol

Can-Fite Biopharma Ltd. Announces New Data from the Phase Ii Advanced Liver Cancer Study

Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies

Can-Fite BioPharma Ltd Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers

Can-Fite Biopharma Ltd. Receives Israel Ministry of Health Approval to Conduct Research with Cannabinoids in Cancer, Inflammation and Obesity at the Company Discovery Labs

Can-Fite BioPharma Ltd. Announces Namodenoson Drug Candidate for Non-Alcoholic Steatohepatitis Treatment

Can-Fite BioPharma Ltd., Annual General Meeting, Dec 09, 2020

Can-Fite BioPharma Ltd. to Report Q3, 2020 Results on Nov 30, 2020

Can-Fite Biopharma Ltd. Announces That Dr. Rifaat Safadi, Principal Investigator of the Company's Phase Ii Study of Namodenoson in the Treatment of Nafld/Nash Delivered A Late-Brweaking Oral Presentation At the Aasld Conference

Can-Fite BioPharma Ltd. Announces Positive Phase III Psoriasis Interim Data Analysis

Can-Fite BioPharma Ltd. to Report Q2, 2020 Results on Aug 27, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies